Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Must have received: anti-PD-1/PD-L1 therapy in combination with platinum-based systemic therapy — first-line

Has progressed on or after treatment with an anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered as part of first-line platinum-based systemic therapy for ES-SCLC

Cannot have received: systemic anticancer therapy including investigational agents

Exception: within 4 weeks before start of study treatment

Has received prior systemic anticancer therapy including investigational agents within 4 weeks before start of study treatment

Cannot have received: radiotherapy

Exception: within 2 weeks of start of study treatment

Has received prior radiotherapy within 2 weeks of start of study treatment

Cannot have received: lung radiation therapy >30 Gray

Exception: within 6 months before the first dose of study treatment

Has received lung radiation therapy >30 Gray (Gy) within 6 months before the first dose of study treatment

Cannot have received: receptor tyrosine kinase (RTK) inhibitor

Has received prior therapy with a receptor tyrosine kinase (RTK) inhibitor

Cannot have received: anti-CTLA-4 therapy

Has received prior therapy with ... anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Cannot have received: anti-ILT4 therapy

Has received prior therapy with ... anti-immunoglobulin-like transcript (ILT)-4

Cannot have received: anti-LAG-3 therapy

Has received prior therapy with ... anti-lymphocyte-activation gene 3 (LAG-3) agents

Cannot have received: anti-PD-1/L1 therapy (permanently discontinued due to treatment-related adverse event)

Has received prior therapy with an anti-PD-1/L1 agent and was permanently discontinued from that treatment due to a treatment-related adverse event

Cannot have received: CDH6-targeted agent

Received prior treatment with a CDH6-targeted agent

Cannot have received: ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (trastuzumab deruxtecan, datopotamab deruxtecan)

Received prior treatment with ... an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan, datopotamab deruxtecan)